Jefferies Financial Group Inc. Buys 40,377 Shares of 10x Genomics (NASDAQ:TXG)

Jefferies Financial Group Inc. boosted its holdings in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 130.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 71,425 shares of the company's stock after buying an additional 40,377 shares during the quarter. Jefferies Financial Group Inc. owned approximately 0.06% of 10x Genomics worth $624,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in shares of 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after purchasing an additional 1,614 shares during the period. GF Fund Management CO. LTD. acquired a new position in 10x Genomics in the 4th quarter valued at $32,000. Signaturefd LLC grew its holdings in 10x Genomics by 134.3% in the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after buying an additional 2,409 shares in the last quarter. Whittier Trust Co. bought a new position in 10x Genomics during the 1st quarter worth $41,000. Finally, US Bancorp DE lifted its holdings in shares of 10x Genomics by 314.5% during the first quarter. US Bancorp DE now owns 5,973 shares of the company's stock worth $52,000 after buying an additional 4,532 shares in the last quarter. Institutional investors own 84.68% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on TXG. The Goldman Sachs Group decreased their price target on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research note on Monday, May 12th. Bank of America boosted their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Thursday, June 26th. Stephens restated an "overweight" rating and set a $14.00 target price on shares of 10x Genomics in a research report on Thursday, May 15th. Barclays lifted their price target on shares of 10x Genomics from $13.00 to $15.00 and gave the company an "overweight" rating in a research report on Friday. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research report on Tuesday, July 29th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $13.50.

Insider Buying and Selling at 10x Genomics

In related news, CFO Adam Taich sold 4,044 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total value of $33,565.20. Following the sale, the chief financial officer directly owned 331,588 shares in the company, valued at approximately $2,752,180.40. The trade was a 1.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Benjamin J. Hindson sold 7,485 shares of the company's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $62,125.50. Following the sale, the insider owned 448,374 shares in the company, valued at $3,721,504.20. The trade was a 1.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,872 shares of company stock worth $173,238 in the last quarter. 9.39% of the stock is currently owned by company insiders.

10x Genomics Stock Down 4.0%

TXG stock traded down $0.51 during mid-day trading on Friday, reaching $12.29. 4,792,434 shares of the company traded hands, compared to its average volume of 3,423,651. The firm's 50 day moving average price is $11.86 and its 200 day moving average price is $10.82. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -9.45 and a beta of 2.03. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 23.22% and a negative net margin of 25.14%. The business had revenue of $172.91 million for the quarter, compared to analysts' expectations of $139.36 million. During the same period last year, the business earned ($0.32) EPS. The business's revenue was up 12.9% on a year-over-year basis. On average, analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.